Researchpaper 29
Association of tamoxifen with meningioma: a
population-based study in Sweden
Jianguang Jia, Jan Sundquista,b and Kristina Sundquista,b
Previousstudiessuggestthathormonetherapymayplayan womendiagnosedwithbreastcancerbutnottreatedwith
importantroleinthedevelopmentofmeningioma.However, tamoxifenhadanincreasedincidenceofmeningioma,
itisunclearwhethermedicationwithtamoxifencanprevent whereastheincidencewasclosetothatofthegeneral
meningioma.Ourstudycohortincludedallwomenwho populationinpatientstreatedwithtamoxifen.Thissuggests
werediagnosedwithbreastcancerbetween1961and2010, thattamoxifenmaypreventthedevelopmentof
andatotalof227535womenwereidentifiedwithbreast meningioma. EuropeanJournalofCancerPrevention
cancerwithamedianageatdiagnosisof63years.Women 25:29–33Copyright©2015WoltersKluwerHealth,Inc.All
diagnosedwithbreastcancerafter1987weredefinedas rightsreserved.
tamoxifenexposed;thosediagnosedwithbreastcancer
EuropeanJournalofCancerPrevention2016,25:29–33
beforeorduring1987weredefinedasnotexposedto
tamoxifen.Standardizedincidenceratios(SIRs)wereused Keywords:breastcancer,meningioma,tamoxifen
tocalculatetheriskofsubsequentmeningioma.Ofthese aCenterforPrimaryHealthCareResearch,LundUniversity/RegionSkåne,Malmö,
women,223developedmeningioma.Forwomenwithout SwedenandbStanfordPreventionResearchCenter,StanfordUniversitySchool
ofMedicine,Stanford,California,USA
tamoxifenexposure,theriskofmeningiomawas
significantlyincreased,withanSIRof1.54(95%confidence CorrespondencetoJianguangJi,MD,PhD,CenterforPrimaryHealthCare
Research,CRC,Building28,Floor11,JanWaldenströmsgata35,Skåne
interval1.30–1.81);theriskwasnotincreasedinthosewith
UniversityHospital,20502Malmö,Sweden
tamoxifenexposure(SIR=1.06,95%confidenceinterval Tel:+4640391382;fax:+4640391370;e-mail:jianguang.ji@med.lu.se
0.84–1.32).Theincreasedriskofmeningiomainwomen
Received4November2014Accepted23December2014
withouttamoxifenexposurepersistedduring10yearsof
follow-up.Inthishistoricalcohortstudy,wefoundthat
Introduction All the above observations suggest that oestrogen may
Meningioma is a common tumour in the central nervous play an important role in the development of menin-
system, and it accounts for 13–26% of all intracranial gioma. It is thus important to examine whether medica-
tumours (Barnholtz-Sloan and Kruchko, 2007; Wiemels tion with tamoxifen, a selective oestrogen receptor
et al., 2010). The only known risk factor for meningioma modulator with an antioestrogenic effect (Al-Mubarak
is ionizing radiation (Preston et al., 2002; El Ghissassi et al., 2014; Nazarali and Narod, 2014), can inhibit or
etal.,2009);otherenvironmentalandlifestyleriskfactors preventthedevelopmentofmeningioma.Tamoxifenhas
showinconclusiveresults(Barnholtz-SloanandKruchko, been used widely to treat patients with oestrogen
2007;Wiemelsetal.,2010).Giventhehigherprevalence receptor-positive breast cancer (Al-Mubarak et al., 2014;
of meningioma in women than in men (ratio 2:1) (Hsu NazaraliandNarod,2014),andwasfirstusedinSweden
et al., 1997; Carroll et al., 2000; Claus et al., 2008), it was inthelate1980s(Fornanderetal.,1989;Chandanosetal.,
hypothesized that hormones may be a risk factor for 2006). To study its influence on the development of
meningioma. Its association with hormones was further meningioma, we tested in this study whether women
supported by evidence from women receiving hormone diagnosedwithbreastcancerandtreatedwithtamoxifen
replacement therapy, who were found to have an have a lower incidence of meningioma compared with
increased risk of meningioma (Claus et al., 2007; Benson women without tamoxifen treatment using a nationwide
etal.,2010;Korhonenetal.,2012).Apossibleassociation population-based cohort study.
was also observed among women using oral contra-
ceptives(Custeretal.,2006;Clausetal.,2007;Korhonen Methods
et al., 2010), and pregnancy and menopausal status were This historical cohort study was approved by the
reported to influence the risk of meningioma (Lambe Regional Ethical Review Board of Lund University,
et al.,1997; Wigertzet al.,2008). Women diagnosedwith Sweden, in 2013 (Diarienummer 2012/795). Patients
breast cancer have an increased risk of meningioma and diagnosedwithbreastcancerduringtheperiod1January
vice versa (Custer et al., 2002; Rao et al., 2009). Some 1961 to 31 December 2010 were identified from the
studies confirmed the expression of oestrogen receptors Swedish Cancer Registry. The Swedish Cancer Registry
in some meningiomas (Black et al., 1996; Carroll et al., was founded in 1958, and has had nationwide coverage
1999; Claus et al., 2008). since 1961. The Swedish Cancer Registry is currently
0959-8278Copyright©2015WoltersKluwerHealth,Inc.Allrightsreserved. DOI:10.1097/CEJ.0000000000000133
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
30 EuropeanJournalofCancerPrevention 2016, Vol25No1
estimatedtohavecloseto100%coverageatthenational cohorts on the basis of the assumption that the pre-
level (Hemminki et al., 2010). It is maintained by the valenceoftamoxifenwas5and50%beforeandafterthe
National Board of Health and Welfare. In Sweden, all year 1987, respectively.
clinicians and pathologists/cytologists are obliged to
In our exposure definition, all the patients diagnosed
reportallnewlydiagnosedprimarycancerstotheCancer
with breast cancer in 1988–2000 were defined as being
Registry. A validation study showed that 99% of the
tamoxifen exposed, which may lead to misclassification
recorded cancer cases are morphologically verified
of exposure. In particular, only those breast cancer
(Hemminki et al., 2010). Only primary tumours are +
patients with ER could be treated with tamoxifen, and
recorded in this register; metastases are excluded. +
around 85% could be diagnosed with ER according to
Women with breast cancer were identified from the
the published literature (Ferno et al., 2000). We thus
Swedish Cancer Registry using the ICD-7 code 170.
calculated the adjusted risk ratio on the basis of the fol-
Only patients with a first primary breast cancer were
lowing formula:
included; patients with a previous cancer, including
breast cancer, were excluded. 1:06¼1:54(cid:2)ð1(cid:3)percentageofmisclassificationÞ
All the patients in our cohort were followed until the þpercentageofmisclassification(cid:2)adjustedriskratio:
diagnosis of meningioma, which was identified from the
−
We assumed that all the patients with ER will not be
Swedish Cancer Registry using the ICD-7 code 1930.
treated with tamoxifen, and they will have the same
Histological confirmation was determined using the
incidence as those breast cancer patients diagnosed
pathologicalanatomicdiagnosticcodes461,465and466.
before 1988 (SIR=1.56). All analyses were carried out
These codes were used during the entire study period.
using SAS, version 9.1 (SAS Institute, Cary, North
Additional linkages were made to the Swedish National
Carolina, USA).
Population and Housing Census (Population and
Housing Census 1960–1990, 2011) to obtain information
on individual-level characteristics, such as year of birth
Results
and sex; to the Cause of Death Register to identify date
In Table 1, we present the basic characteristics of
ofdeath;andtotheEmigrationRegistrytoidentifydate
Swedishwomendiagnosedwithbreastcancerfrom1961
of emigration. All linkages were performed using indivi-
to 2000. A total of 227535 women were diagnosed with
dual national identification numbers, which were
breastcancer,withamedianageatdiagnosisof63years.
replaced with serial numbers to preserve anonymity.
Amongthesewomen,223developedmeningiomaduring
Wecalculatedperson-yearsatriskforourcohortfromthe 1715497 person-years of follow-up. The number of
date of diagnosis of first primary breast cancer to the
earliestofthefollowing:dateofdiagnosisofmeningioma,
death, emigration and end of the study period (31 Table1 BasiccharacteristicsofSwedishwomendiagnosedwith
breastcancerin1961–2010
December 2010). We estimated the risk of meningioma
in our cohort using standardized incidence ratios (SIRs), Person-yearsof Numberof
N(%) follow-up meningiomacases
which were calculated as the ratio of the observed to
expected numbers of cases (Breslow and Day, 1987;
Nottamoxifenexposed(1961–1987)
Breastcancers 98681 964859 145
Rothman and Greenland, 1998). The expected number Ageatdiagnosis(years)
of cases was calculated by multiplying the observed <50 19067(19.3)
50–59 20054(20.3)
person-yearsatriskbytheincidencerateofmeningioma 60–69 24466(24.8)
for all individuals without a diagnosis of primary breast 70+ 35094(35.6)
cancer. SIRs were standardized by 5-year age group and
Tamoxifenexposed(1988–2010)
Numberofbreast 128854 750638 78
5-year time interval. For the SIRs, 95% confidence
cancers
intervals (CIs) were calculated assuming a Poisson dis- Medianageat 63
entry(years)
tribution and rounded to two decimal places (Esteve
Ageatdiagnosis(years)
et al., 1994). To exclude surveillance bias, all meningio- <50 22777(17.7)
mas diagnosed within 1 year of follow-up after the pri- 50–59 28890(22.4)
60–69 31550(24.5)
mary breast cancer were excluded. As tamoxifen has
70+ 41277(32.0)
been used widely in Sweden since the late 1980s, we Totalcohort(1961–2010)
defined patients with a diagnosis of breast cancer before Numberofbreast 227535 1715497 223
cancers
the end of December 1987 (years 1961–1997) as not Medianageat 63
exposed to tamoxifen and those diagnosed with breast entry(years)
cancerin1988–2010astamoxifenexposed.Asthisstudy Ageatdiagnosis(years)
<50 41844(18.4)
isanationwidestudywithatotalof227535patientswith 50–59 48944(21.5)
breast cancer, we have 100% power to detect an 60–69 56016(24.6)
70+ 76371(33.6)
increasing prevalence of tamoxifen between the two
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
TamoxifenandmeningiomaJietal. 31
womenwithouttamoxifenexposure(diagnosedbetween Table3 Adjustedriskratioaccordingtothepercentageof
misclassificationoftheexposure
1961 and 1987) was 98681; 128854 women (diagnosed
between1988and2010)hadtamoxifenexposure.Atotal Misclassification(%) Adjustedriskratio
of 145 meningiomas were found in women without
0.95 1.03
tamoxifen exposure and 78 meningiomas were found in 0.90 1.01
women with tamoxifen exposure. 0.85 0.98
0.80 0.94
0.75 0.90
The risk of meningioma in our cohort is presented in
0.70 0.85
Table 2 according to tamoxifen exposure status. For
women without tamoxifen exposure, the risk of menin-
gioma was significantly increased, with an SIR of 1.54
incidence of meningioma in women diagnosed with
(95% CI 1.30–1.81). By contrast, the risk of meningioma breast cancer during 1988–2010, when tamoxifen was
was not increased in women with tamoxifen treatment
used widely in Sweden, was close that in the general
(SIR=1.06,95%CI0.84–1.32).Theriskofmeningioma
population, suggesting that tamoxifen may prevent the
was further analysed by follow-up interval and age at
development of meningioma.
diagnosisofbreastcancer.Forwomenwithouttamoxifen
exposure, the increased risk of meningioma can persist The increased risk of meningioma in women diagnosed
for 10 years after the first breast cancer, and the risk was withbreastcancerbefore1987isinagreementwithafew
increasedforwomendiagnosedwithbreastcancerbefore
previousreports(Markopouloset al.,1998;Malmer et al.,
50yearsandafter59years.Inaddition,wecalculatedthe 2000; Custer et al., 2002; Rao et al., 2009). One Swedish
risk of meningioma among breast cancer patients diag- studyfoundtherelativeriskofmeningiomatobearound
nosed between 1988 and 2000 and those between 2001 1.6 after the diagnosis of breast cancer (Malmer et al.,
and 2010, separately.TheSIR was 1.08 (N=55, 95%CI 2000). Another study in the USA using the Washington
0.81–1.41) for those diagnosed between 1988 and 2000 StateCancerRegistryfoundthattheriskofmeningioma
and 1.01 (N=23, 95% CI 0.64–1.51) for those diagnosed inwomenwithbreastcancerandtheriskofbreastcancer
between 2001 and 2010. inwomenwithmeningiomawereincreased(Custeretal.,
2002). One subsequent study confirmed the observed
InTable3,wepresenttheadjustedriskratioonthebasis
association between meningioma and breast cancer in
of the percentage of misclassification of exposure. The women, but not in men (Rao et al., 2009). The strong
adjusted risk ratio decreased with an increased percen-
association between meningioma and breast cancer sug-
tage of misclassification of exposure. The risk ratio was
geststhatthetwotumourtypesshareaetiologicalfactors.
1.01 when misclassification of exposure was 10%.
One explanation for the increased incidence of menin-
giomaafterbreastcancercouldberelatedtotheradiation
Discussion and chemotherapy used to treat primary cancers.
In this historical population-based cohort study, we However, the observed increase in the risk of menin-
identifiedatotalof227535womendiagnosedwithbreast gioma in our study persisted for 10 years of follow-up.
cancer during 1961–2010. The main finding is that the This suggests that the treatment effect may only play a
incidence of meningioma was significantly increased in small role because therapeutic effects are usually
women diagnosed with breast cancer between 1961 and observedinthelatefollow-upperiodinsteadoftheinitial
1987, when tamoxifen was not used for the treatment of follow-up period (Ji and Hemminki, 2006). Another
breast cancer in Sweden. In addition, we found that the explanationisthatthetwoprimarycancerssharegenetic
orenvironmental riskfactors.However, apreviousstudy
suggests that the contribution of BCRA1 and BCRA2
Table2 RiskofmeningiomainSwedishwomenwithabreast
cancerdiagnosisin1961–2010 mutationstothedevelopmentofmeningiomaisminimal
(Kirschetal.,1997).Onthebasisofourdiscussionabove,
Nottamoxifenexposed the strong association between breast cancer and
(1961–1987) Tamoxifenexposed(1988–2010)
meningiomas may be related to oestrogen, which could
O SIR 95%CI O SIR 95%CI contribute to the development of these two types of
Overall 145 1.54 1.30 1.81 78 1.06 0.84 1.32 tumour.
Timeafterbreastcancerdiagnosis(years)
1–4 46 1.73 1.27 2.31 31 0.95 0.64 1.35 Women with breast cancer have been treated with
5–9 50 2.10 1.56 2.77 27 1.10 0.72 1.60 tamoxifen since the late 1980s in Sweden (Rutqvist,
10+ 49 1.12 0.82 1.48 20 1.22 0.74 1.88
Ageatdiagnosisofbreastcancer(years) 2004), and the prognosis has been found tobe markedly
<50 32 1.46 1.00 2.07 20 1.32 0.81 2.05 improved among patients with oestrogen receptor-
50–59 30 1.33 0.90 1.90 25 1.04 0.67 1.54
positive tumours. In addition, many studies have exam-
60+ 83 1.66 1.32 2.06 33 0.95 0.66 1.34
ined the effectiveness of tamoxifen in preventing breast
Boldtype:95%CIdoesnotinclude1.00. cancer(Freedmanetal.,2003;KramerandBrown,2004).
CI, confidence interval; O, observed number of cases; SIR, standardized
incidenceratio. It was found that administration of tamoxifen to women
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
32 EuropeanJournalofCancerPrevention 2016, Vol25No1
dailyfor5yearscanreducetheirriskofdevelopingbreast varied somewhat depending on the age at diagnosis
cancer by about one-half (Freedman et al., 2003; Kramer (Kemetli et al., 2009). In addition, treatment with tamox-
and Brown, 2004). However, it is not known whether ifen at the beginning lasted only for 2 years, and then
tamoxifen can prevent the development ofmeningioma, increased to 5 years (Ferno et al., 2000). The increased
although oestrogen may play an important role in the prevalenceandtimeforthetreatmentofbreastcancerwith
development of meningioma. tamoxifen suggest that the risk of meningioma could be
varied depending on the time period. Indeed, our study
Inthisstudy,wefoundthattheincidenceofmeningioma
found that the risk of meningioma was somewhat higher
inbreastcancerpatientsdiagnosedafter1987andtreated
among those patients diagnosed between 1988 and 2000
with tamoxifen was close to that in the general popula-
compared with those between 2001 and 2010, further
tion.Toourknowledge,nopreviousstudyhasexamined
supporting the evidence that treatment with tamoxifen
whether tamoxifen can inhibit the development of
maydecreasetheriskofmeningioma.Itisknownthatthe
meningioma. Our data suggest that tamoxifen may inhi-
therapyanddiagnosisofmeningiomahavechangedduring
bit the development of meningioma, which may be
thestudyperiod,buttheSIRinthisstudywasadjustedfor
helpful for individuals at high risk of meningioma, such
the time period, which can minimize the confounding
as those with neurofibromatosis type 2 gene (NF2)
effect. In addition, adjuvant chemotherapy for breast can-
mutations: mutations in the NF2 gene may account for
cer has also increased during the study period (Kemetli
half of all meningioma cases (Simon et al., 2007). Two et al., 2009), but no evidence suggests that adjuvant che-
small studies explored the effect of tamoxifen treatment
motherapy could protect against the development of
on meningioma, but the results were inconclusive
meningioma.Themortalityofbreastcancerhasdecreased
(Markwalder et al., 1985; Goodwin et al., 1993). A study
continuously during the past decades (Schopper and De
by Markwalder et al. (1985) in which six meningioma
Wolf, 2009), but the risk of meningioma could be higher
patientsweretreatedwithtamoxifenfoundnosignificant
among women with low mortality because of the long
improvement in tumour growth. Another study by
duration of follow-up compared with those with high
Goodwin et al. (1993), based on 21 patients with non-
mortality. Data on individual-level risk factors such as
resectable refractory meningiomas, did not recommend
alcohol consumption, smoking and dietary factors were
the use of tamoxifen in refractory meningioma.
lacking,whichmayhavepartlyconfoundedourconclusion.
However,thereisnoconclusiveevidencethatthesefactors
Thepresentstudyhassomeimportantstrengths.First,all
areassociated withmeningioma,which suggeststhattheir
primary breast cancers and subsequent meningiomas
effects are minimal.
wereidentifiedfromtheSwedishCancerRegistry,which
hashighqualityandnationwidecoverage.Diagnosticbias
isunlikelybecausetheSwedishCancerRegistryisbased Conclusion
onthecompulsoryclinicalreportsprovidedbyphysicians, Women diagnosed with breast cancer who were not
pathologists,andcytologists,ensuringdiagnosticaccuracy treated with tamoxifen had an increased risk of menin-
at the national level. In addition, this study is a nation- gioma,suggestingthatthetwotypesoftumourmayshare
wide studyandenoughpatientswereincludedtoensure aetiological factors such as oestrogen. By contrast, the
reliableriskestimates.Theprospectivestudydesignand incidence of meningioma in women with breast cancer
the completeness of the follow-up of patients are other whoweretreatedwithtamoxifenwasclosetothatinthe
major advantages of the present study. general population, which suggests that tamoxifen may
prevent the development of meningioma.
One major limitation of this study is that data on medi-
cationwithtamoxifeninourcohortattheindividuallevel
Acknowledgements
werelacking,andwedefinedtamoxifenexposurebyyear
The authors wish to thank the CPF’s Science Editor,
ofdiagnosisofbreastcanceronthebasisofevidencethat
Stephen Gilliver, for his valuable comments on the text.
tamoxifenhasbeenusedwidelyinSwedensincethelate
This work was supported by grants awarded to
1980s. However, such a definition may have led to non-
Dr Kristina Sundquist by the Swedish Research Council
differential misclassification of tamoxifen exposure,
(K2009-70X-15428-05-3; K2012-70X-15428-08-3) and to
thereby diluting the true observations and biasing our
Dr Jan Sundquist by the Swedish Council for Working
results towards the null. The adjusted risk ratio
LifeandSocialResearch(2007-1754),aswellasbyALF
decreased with an increased percentage of misclassifica-
funding from Region Skåne awarded to Jan Sundquist,
tion (Table 3), providing further evidence that non-
Kristina Sundquist and Dr Jianguang Ji.
differential misclassification will bias our results towards
thenull.TheuseoftamoxifenwasinfrequentinSweden J.J., K.S. and J.S. were responsible for the study concept
before1990,butincreasedcontinuouslyduringthe1990s anddesign.J.S.,K.S.andJ.J.obtainedfunding.K.S.and
(Kemetlietal.,2009).In2005,theproportionofoperable J.S. acquired the data. J.J. analysed and interpreted the
breast cancer patients treated with adjuvant endocrine data.J.J.draftedthemanuscript.J.J.,K.S.andJ.S.revised
therapy was around 60–80%, although the prevalence the manuscript for important intellectual content.
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
TamoxifenandmeningiomaJietal. 33
Conflicts ofinterest GoodwinJW,CrowleyJ,EyreHJ,StaffordB,JaeckleKA,TownsendJJ(1993).A
There are no conflicts of interest. phaseIIevaluationoftamoxifeninunresectableorrefractorymeningiomas:a
SouthwestOncologyGroupstudy.JNeurooncol15:75–77.
HemminkiK,JiJ,BrandtA,MousaviSM,SundquistJ(2010).TheSwedishFamily-
References CancerDatabase2009:prospectsforhistology-specificandimmigrantstu-
dies.IntJCancer126:2259–2267.
Al-MubarakM,TibauA,TempletonAJ,CesconDW,OcanaA,SerugaB,AmirE
HsuDW,EfirdJT,Hedley-WhyteET(1997).Progesteroneandestrogenrecep-
(2014).Extendedadjuvanttamoxifenforearlybreastcancer:ameta-analysis. torsinmeningiomas:prognosticconsiderations.JNeurosurg86:113–120.
PLoSOne9:e88238.
JiJ,HemminkiK(2006).Secondprimarymalignanciesamongpatientswithsoft
Barnholtz-Sloan JS, KruchkoC (2007). Meningiomas: causes and risk factors. tissuetumorsinSweden.IntJCancer119:909–914.
NeurosurgicalFocus23:E2.
Kemetli L, Rutqvist LE, Jonsson H, Nystrom L, Lenner P, Tornberg S (2009).
BensonVS,PirieK,GreenJ,BullD,CasabonneD,ReevesGK,BeralV,Million
Temporaltrendsintheuseofadjuvantsystemictherapyinbreastcancer:a
Women Study Collaborators (2010). Hormone replacement therapy and populationbasedstudyinSweden1976–2005.ActaOncol48:59–66.
incidenceofcentralnervoussystemtumoursintheMillionWomenStudy.IntJ
KirschM,ZhuJJ,BlackPM(1997).AnalysisoftheBRCA1andBRCA2genesin
Cancer127:1692–1698.
sporadicmeningiomas.GenesChromosomesCancer20:53–59.
BlackP,CarrollR,ZhangJ(1996).Themolecularbiologyofhormoneandgrowth
Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A (2010).
factorreceptorsinmeningiomas.ActaNeurochirSuppl65:50–53.
Exogenous sex hormone use and risk of meningioma: a population-based
BreslowNE,DayNE(1987).Statisticalmethodsincancerresearch.Volume2–
case–controlstudyinFinland.CancerCausesControl21:2149–2156.
Thedesignandanalysisofcohortstudies.Lyon,France:InternationalAgency
KorhonenK,AuvinenA,LyytinenH,YlikorkalaO,PukkalaE(2012).Anationwide
forResearchonCancer. cohort study on the incidence of meningioma in women using post-
CarrollRS,ZhangJ,BlackPM(1999).Expressionofestrogenreceptorsalpha menopausalhormonetherapyinFinland.AmJEpidemiol175:309–314.
andbetainhumanmeningiomas.JNeurooncol42:109–116.
KramerR,BrownP(2004).Shouldtamoxifenbeusedinbreastcancerpreven-
CarrollRS,BrownM,ZhangJ,DiRenzoJ,FontDeMoraJ,BlackPM(2000). tion?DrugSaf27:979–989.
Expressionofasubsetofsteroidreceptorcofactorsisassociatedwithpro- LambeM,CooganP,BaronJ(1997).Reproductivefactorsandtheriskofbrain
gesterone receptor expression in meningiomas. Clin Cancer Res tumors:apopulation-basedstudyinSweden.IntJCancer72:389–393.
6:3570–3575.
MalmerB,TavelinB,HenrikssonR,GronbergH(2000).Primarybraintumoursas
ChandanosE,LindbladM,JiaC,RubioCA,YeW,LagergrenJ(2006).Tamoxifen second primary: a novel association between meningioma and
exposureandriskofoesophagealandgastricadenocarcinoma:apopulation- colorectalcancer.IntJCancer85:78–81.
based cohort study of breast cancer patients in Sweden. Br J Cancer MarkopoulosC,SampalisF,GivalosN,GogasH(1998).Associationofbreast
95:118–122. cancerwithmeningioma.EurJSurgOncol24:332–334.
Claus EB, BlackPM, Bondy ML, Calvocoressi L, Schildkraut JM, Wiemels JL, MarkwalderTM, Seiler RW,ZavaDT(1985). Antiestrogenictherapyof menin-
WrenschM(2007).Exogenoushormoneuseandmeningiomarisk:whatdo giomas–apilotstudy.SurgNeuro24:245–249.
wetellourpatients?Cancer110:471–476.
NazaraliSA,NarodSA(2014).Tamoxifenforwomenathighriskofbreastcancer.
ClausEB,ParkPJ,CarrollR,ChanJ,BlackPM(2008).Specificgenesexpressed BreastCancer6:29–36.
in association with progesterone receptors in meningioma. Cancer Res PopulationandHousingCensus1960-1990(2011).StatisticsSweden(SCB).
68:314–322.
Available at: http://www.scb.se/Pages/Product____7158.aspx. [Accessed
Custer BS, Koepsell TD, Mueller BA (2002). The association between breast 22March2011].
carcinomaandmeningiomainwomen.Cancer94:1626–1635.
PrestonDL,RonE,YoneharaS,KobukeT,FujiiH,KishikawaM,etal.(2002).
Custer B, Longstreth WT Jr, Phillips LE, Koepsell TD, van Belle G (2006). Tumors of the nervous system and pituitary gland associated with atomic
Hormonal exposures and the risk of intracranial meningioma in women: a bombradiationexposure.JNatlCancerInst94:1555–1563.
population-basedcase–controlstudy.BMCCancer6:152. RaoG,GiordanoSH,LiuJ,McCutcheonIE(2009).Theassociationofbreast
ElGhissassiF,BaanR,StraifK,GrosseY,SecretanB,BouvardV,etal.(2009). cancer and meningioma in men and women. Neurosurgery 65:483–489,
A review of human carcinogens – part D: radiation. Lancet Oncol discussion489.
10:751–752. RothmanKJ,GreenlandS(1998).Modernepidemiology,2nded.Philadelphia,
Esteve J, Benhamou E, Raymond L (1994). Statistical methods in cancer PA:Lippincott-RavenPublishers.
research.Lyon,France:IARC. RutqvistLE(2004).Adjuvantendocrinetherapy.BestPractResClinEndocrinol
FernoM, Stal O,Baldetorp B,HatschekT,KallstromAC,MalmstromP,etal. Metab18:81–95.
(2000).Resultsoftwoorfiveyearsofadjuvanttamoxifencorrelatedtosteroid Schopper D, de Wolf C (2009). How effective are breast cancer screening
receptor and S-phase levels. South Sweden Breast Cancer Group, and programmes by mammography? Review of the current evidence. Eur J
South-East Sweden Breast Cancer Group. Breast Cancer Res Treat Cancer45:1916–1923.
59:69–76. SimonM,BostromJP,HartmannC(2007).Moleculargeneticsofmeningiomas:
FornanderT,RutqvistLE,CedermarkB,GlasU,MattssonA,SilfverswärdC,etal. frombasicresearchtopotentialclinicalapplications.Neurosurgery60:787-
(1989).Adjuvanttamoxifeninearlybreastcancer:occurrenceofnewprimary –798.Discussion787–798.
cancers.Lancet1:117–120. WiemelsJ,WrenschM,ClausEB(2010).Epidemiologyandetiologyofmenin-
FreedmanAN,GraubardBI,RaoSR,McCaskill-StevensW,Ballard-BarbashR, gioma.JNeurooncol99:307–314.
GailMH(2003).EstimatesofthenumberofUSwomenwhocouldbenefit WigertzA,LonnS,HallP,AuvinenA,ChristensenHC,JohansenC,etal.(2008).
from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst Reproductivefactorsandriskofmeningiomaandglioma.CancerEpidemiol
95:526–532. BiomarkersPrev17:2663–2670.
Copyright r 2016 Wolters Kluwer Health, Inc. All rights reserved.
